Core Viewpoint - A class action lawsuit has been filed against Super Micro Computer, Inc. for alleged violations of federal securities laws, impacting investors who purchased securities between April 30, 2024, and March 19, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who acquired Super Micro securities during the specified class period [2]. - Allegations include failure to disclose material weaknesses in the company's compliance with export control laws, leading to misleading statements about the company's business and prospects [3][9]. Group 2: Investor Actions - Investors affected by the alleged violations are encouraged to join the lawsuit and can request to be appointed as lead plaintiff by May 26, 2026 [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6]. - The firm's mission focuses on restoring investor capital and ensuring corporate accountability to maintain market integrity [6].

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws, following allegations of misleading revenue growth claims related to its product ASCENIV, which reported significant year-over-year growth that may not reflect actual market demand [1][2]. Group 1: Company Performance - ADMA Biologics reported $363 million in net revenue for ASCENIV, indicating a 51% year-over-year growth [2]. - The company's annual report suggested that commercial execution would enhance demand utilization while maintaining cost discipline [2]. Group 2: Allegations and Market Reaction - Culper Research's short report accused ADMA of achieving revenue growth through "classic channel stuffing," suggesting that actual underlying demand is declining [2]. - There is a notable discrepancy between the reported 20% revenue growth and the alleged 3% decline in underlying demand, highlighting potential issues in the company's financial reporting [2]. - Following the release of the short-seller report on March 24, 2026, ADMA's stock experienced a sharp decline [2].

Core Viewpoint - Coty Inc. is facing a securities class action lawsuit due to alleged misleading statements regarding its business performance, particularly following its Q2 2026 earnings report which revealed significant operational issues and the unexpected departure of its CEO, leading to an over 8% drop in share price on the announcement day [1][8]. Group 1: Lawsuit Details - The class action lawsuit aims to represent investors who acquired Coty common stock between November 5, 2025, and February 4, 2026 [1]. - Hagens Berman, a national shareholders rights firm, is investigating claims that Coty violated federal securities laws and is encouraging affected investors to report their losses [2][10]. - The lawsuit focuses on the accuracy of Coty's disclosures regarding business trends in its Prestige and Consumer Beauty segments [4]. Group 2: Financial Performance - On November 5, 2025, Coty assured investors of expected improvements in sales trends for fiscal 2026, reaffirming its adjusted EBITDA target of $1 billion [5]. - The complaint alleges that Coty failed to disclose underperformance in the Consumer Beauty market, increased marketing costs compressing margins, and slowing growth in Prestige fragrances [6]. - The Q2 2026 financial results revealed a more than 70% decline in operating income for Consumer Beauty compared to the previous year, while Prestige's operating income fell over 18% [7]. Group 3: Management Statements - During the earnings call on February 5, 2026, management projected a mid-single-digit decline in like-for-like revenue trends for Q3, primarily due to significant declines in Consumer Beauty [8]. - Management indicated that retailer destocking and an intensified promotional environment were headwinds affecting net sales and gross margins [8]. Group 4: Investigation Focus - The investigation by Hagens Berman is examining whether Coty intentionally misled investors about its segment business trends and the circumstances surrounding the CEO's abrupt departure [9].

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Picard Medical, Inc. (NYSE: PMI). Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/picard-medical-inc-loss-submission-form/?id=184870&from=3 CLASS PERIOD: Septembe ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Lufax Holding Ltd regarding a class action lawsuit due to alleged misleading statements and inadequate internal controls during a specified class period [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from April 7, 2023, to January 26, 2025 [3]. - Allegations include that Lufax lacked adequate internal controls, and certain financial results were materially misstated, leading to false and misleading statements about the company's business and prospects [3]. - The deadline for shareholders to register for the class action is May 20, 2026, and there is no cost or obligation to participate [4]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm is dedicated to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [5].

Group 1 - A class action lawsuit has been filed against Concorde International Group, Ltd. on behalf of investors who purchased shares between April 21, 2025, and July 14, 2025 [1][2] - Concorde is a Singapore-based provider of security services catering to commercial, financial, industrial, and government clients [2] - Following its IPO in April 2025, Concorde's stock experienced extreme volatility, with a significant price surge followed by an abrupt decline of approximately 80% on July 10, 2025, due to reports of a coordinated stock promotion scheme [3] Group 2 - Investors who acquired Concorde securities during the class period have until May 18, 2026, to seek appointment as lead plaintiff representatives [2] - Berger Montague, the law firm handling the case, has a strong track record in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [5]

Core Viewpoint - Coty Inc. is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its growth prospects and financial performance during the fiscal year 2026 [5]. Group 1: Lawsuit Details - The Schall Law Firm is leading the class action lawsuit against Coty Inc. for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Coty securities between November 5, 2025, and February 4, 2026, are encouraged to participate in the lawsuit before the deadline of May 22, 2026 [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [4]. Group 2: Allegations Against Coty - The lawsuit claims that Coty made overwhelmingly positive statements about its growth prospects, despite evidence of slowing growth and underperformance in its Consumer Beauty segment [5]. - The company's increasing marketing expenditures are said to negatively impact its profit margins, contributing to the misleading nature of its public statements [5]. - Investors reportedly suffered damages when the market became aware of the true state of Coty's financial performance [5].

Core Viewpoint - A class action lawsuit has been filed against Gemini Space Station, Inc. by Berger Montague on behalf of investors who acquired shares during the specified Class Period, alleging misleading statements in the IPO documents [1][3]. Company Overview - Gemini Space Station, Inc. is a cryptocurrency platform that operates a digital asset exchange and related services, headquartered in New York [2]. Legal Action Details - The lawsuit claims that the IPO Offering Documents contained materially false and misleading statements regarding the viability of the Company's core business and its international expansion strategy, as well as the risk of requiring a costly restructuring [3]. - Investors have until May 18, 2026, to seek appointment as lead plaintiff representative of the class [2]. Recent Developments - On February 5, 2026, Gemini announced a strategic shift towards a prediction market-focused model, referred to as "Gemini 2.0," which included workforce reductions and exiting multiple international markets. Following this announcement, the stock price fell by $0.64, or 8.72%, closing at $6.70 [4]. - The stock further declined on February 17, 2026, after the Company reported preliminary financial results showing increased operating expenses and significant executive departures, leading to a drop of $0.975, or 12.9%, closing at $6.585 [5].

Core Viewpoint - Eagle Bancorp, Inc. is under investigation for possible securities fraud, with a potential class action being considered for affected investors [1] Financial Performance - Eagle's stock price dropped by $2.41, or 11.4%, closing at $18.78 per share on April 24, 2025, following a significant decline in net income to $1.7 million from $15.3 million in the previous quarter [2] - The company reported a $5.1 million decrease in net interest income, a $0.9 million increase in noninterest expenses, and a $14.1 million rise in provision expense [2] - A further decline occurred on July 24, 2025, when intraday share prices fell by as much as 22% after a second quarter report revealed a $71.5 million sequential decrease in net income [2] - This second decline was primarily due to a $111.9 million increase in provision expense aimed at addressing valuation pressures in the office portfolio [2] Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, with a history of recovering over $5.5 billion for investors [2]

Group 1 - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Tandem Diabetes Care, Inc. and may file a class action on behalf of investors [1] - Tandem's stock price fell by $2.87, or 19.9%, closing at $11.52 per share on August 7, 2025, due to the disclosure of a malfunction in its insulin pumps [2] - The malfunction could lead to a discontinuation of insulin delivery, potentially resulting in hyperglycemia and requiring hospitalization [2] Group 2 - Tandem had already distributed notices to affected customers regarding the malfunction between July 22 and 24, 2025, prior to the public market disclosure [2] - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [3]